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INTRODUCTION
Cervical cancer is the second most common gynecologic malig­
nancy in the world. The major steps required for cervical carci­
nogenesis include human papillomavirus (HPV) infection, HPV 
persistence, progression to precursor lesions, and invasion [1]. 
The majority of cervical cancer cases are caused by persistent 
infection with at least one of the high­risk (HR) carcinogenic HPV 
types [2]. Consequently, it has been proposed that, like the HPV 
DNA test, highly sensitive HPV detection methods may be 
able to strengthen the efficacy of population­based screening 
programs, either as a sole screening tool or as an adjunct to 
current cervical cancer triage. Hybrid Capture 2 (HC2, Qiagen, 
Gaithersburg, MD, USA), mostly used as an HPV detection me  thod, 
can detect the DNA of the 13 HR and 5 low­risk HPV types that 
most commonly affect the cervix. However, HC2 is unable to 
determine specific HPV types, and HPV 16 and HPV 18 geno­
types are responsible for causing the majority of all cervical 
cancers [3]. Thus, another method is necessary for specific HPV 
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Objective: To validate the efficacy of Seeplex HPV4A ACE for the detection of high­risk (HR) human papillomavirus (HPV) and 
HPV 16 and/or HPV 18 genotypes as compared to the PCR method and the Cervista HPV assays in cervical swab samples.
Methods: Besides liquid­based cytology, additional 97 cervical swab samples were collected for HPV genotyping by HPV4A ACE, 
Cervista HPV assays, and PCR method. To check the statistical differences, we also conducted the paired proportion test, Cohen’
s κ statistic, and a receiver operating characteristic curve.
Results: Seeplex HPV4A ACE and the Cervista HPV HR showed substantial agreement with PCR for detection of HR HPVs (88.3%, 
κ=0.767 and 81.7%, κ=0.636, respectively). Seeplex HPV4A ACE also showed substantial agreement with the Cervista HPV 16/18 
test (89.5%, κ=0.628). Additionally, the sensitivity and specificity of Seeplex HPV4A ACE and Cervista HPV HR were 91.4% vs. 
84.5% and 73.4%, vs. 72.7%, respectively, when those higher than low­grade squamous intraepithelial lesions were regarded as 
abnormalities. HPV genotyping for HPV 16/18 detected cervical intraepithelial neoplasias (CINs) better than HR HPV tests (66.7% 
vs. 24.6% by HPV4A ACE, 52.6% vs. 25.9% by Cervista HPV assays in CIN II or more, relatively).
Conclusion: Seeplex HPV4A ACE is an effective method as the PCR and the Cervista HPV assays for the detection of HR HPVs and 
for genotyping of HPV 16 and 18.
Keywords: Cervista HPV HR, Cervista HPV 16/18, High­risk HPV, HPV 16, HPV 18, Seeplex HPV4A ACE
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genotyping.
Recently, two novel DNA test methods for HPV detection 
and genotyping have been developed, Seeplex HPV4A ACE 
(Seegene Inc., Seoul, Korea) and the Cervista HPV assays (Ho­
logic Inc., Madison, WI, USA). In contrast to other commercially 
available HPV genotyping methods, Seeplex HPV4A ACE is 
DPO­based multiplex PCR. HPV 16 and/or 18 genotyping and 
16 HPV HR type and HPV low risk HPV 6/11 screening can be 
done with one PCR test. The Cervista HPV HR and 16/18 tests 
uses the Invader chemistry (Hologic Inc.), a signal amplifica­
tion method for detection of specific nucleic acid sequences. 
The Cervista HPV HR is designed for detection of 14 HPV types. 
This method uses two types of isothermal reactions, including 
a primary reaction that occurs on the targeted DNA sequence 
and a secondary reaction that produces a fluorescent signal. 
The Cerivsta HPV assays must be conducted separately, but 
Seeplex HPV4A ACE is so robust that physicians can obtain 
HPV results in a single test. The purpose of this study was to 
validate the sensitivity of Seeplex HPV4A ACE for the detec­
tion of HR HPV DNA and HPV 16 and/or HPV 18 genotypes, as 
compared to the PCR method, the Cervista HPV HR, and Cerv­
ista HPV 16/18, in cervical swab samples. Finally, we evaluated 
the sensitivity and specificity of these HPV DNA tests in corre­
lation with cytologic results.
MATERIALS AND METHODS
1. Study population, specimen collection, and histologic 
examination
Women were enrolled who were referred to the Colposcopy 
Clinic in Korea University Guro Hospital due to abnormal cyto  logy 
between April and June 2010. A cervical specimen for liquid­
based cytology, along with simultaneous HPV DNA detection 
by the HC2 assay, was collected from each patient. Genomic 
DNA was extracted from each sample, and the HPV DNA tests 
were performed by HPV4A ACE, PCR method, Cervista HPV 
HR assay, and Cervista HPV 16/18 test on the same specimen. 
Among them, we used only samples of HPV­positive women 
by HC2 assay due to the difficulty of HC2­negative sample col­
lection as limitation of this retrospective study. Colposcopic 
ex  aminations were performed in all women with abnormal cer­
vical cytology.  Histologic verifications by punch biopsy were 
performed in women with abnormal colposcopic findings.
2. Liquid-based cytology
A Cervex­Brush (Rovers Medical Devices, Oss, Netherlands) 
was used to obtain samples from the uterine cervix. The brush 
was immediately rinsed in a vial of PreservCyt solution (Hologic 
Inc.). The vial was placed in the ThinPrep Processor (Hologic 
Inc). The ThinPrep slide was then fixed in ethanol and stained 
with Papanicolaou’s stain. The number of epithelial cells on 
these slides was estimated from the number of cells contained 
within computer­derived coordinates for 50 random fields 
located within a 20­mm diameter circular area where the cells 
were deposited. The diagnoses were made using the 2001 
Bethesda System for cervical cytology.
3. HC2 assay
HPV DNA testing by the HC2 assay was performed with the 
HC2 assay system according to the manufacturer’s protocol 
(Qiagen). The specimens were denatured at 65
oC for 45 min­
utes and hybridized under high­stringency conditions with 
a mixture of RNA probes that detects 13 different oncogenic 
HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. 
The resultant DNA­RNA hybrids were captured on the sur­
face of the microtiter plate wells coated with an anti­DNA­
RNA hybrid antibody. The immobilized hybrids were then 
reacted with an alkaline phosphatase­conjugated antihybrid 
monoclonal antibody. Light intensity was measured with a 
luminometer. The recommended positivity threshold of 1 pg/
mL was used as a cutoff, and all specimens with a relative light 
unit/control (RLU/CO) ratio of ≥1.0 were considered positive. 
4. PCR method
PCR was conducted in a final reaction volume 20 µL contain­
ing 0.1 µg of isolated DNA from a cervical swab, 1 µL of forward 
(F) and reverse (R) primer (General (F): 5’­TTTGTTACTGTG­
GTAGATACTAC­3’, General (R): 5’­GAAAAATAAACTGTAAAT­
CATATTC­3’, HPV 16 (F): 5’­TTTGTTACTGTTGTTGATACTACAC­
GC­3’, HPV 16 (R): 5’­GAAAAATAAACTGTAAATCATATTCCTC­3’, 
HPV 18 (F): 5’­TTTGTTACTGTGGTAGATACCAC TCGC­3’, HPV 
18 (R): 5’­GAAAAATAAACTGCAAATCATATTCCTC­3’, 10 pmole/
µL) and 10 µL of 2X Master Mix (Lucigen, Middleton, WI, USA). 
Here, general primers were common primers to confirm HR 
HPV. After a pre­heating step at 94
oC for 4 minutes, 40 ampli­
fication cycles were carried out in the thermal cycler under 
the following conditions: denaturation at 94
oC for 1 minutes, 
annealing for 2 minutes and extension at 72
oC for 90 seconds. 
Amplification was completed with a final extension step at 
72
oC for 4 minutes. The amplified PCR products were sepa­
rated on 4% agarose gel containing ethidium bromide.
5. Seeplex  HPV4A ACE screening
Seeplex HPV4A ACE is designed for detection of HPV 16 and/
or HPV 18, screening for 16 HPV HR types (i.e., 26, 31, 33, 35, 
39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82), and screening 
for HPV low risk types 6/11. The residual cells in the PreservCyt Usefulness of HPV4A ACE to detect high risk HPV
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solution were centrifuged at 13,000 ×g for 15 minutes, and 
the cell pellets were resuspended in 100 µL of phosphate­
buffered saline. The resuspended cell pellets were added to a 
Qiamp DNA mini Kit (Cat. No. 51304, Qiagen Inc., Valencia, CA, 
USA). The extraction of total DNA was performed according to 
the manufacturer’s instructions. HPV DNA testing by the See­
plex HPV4A ACE was performed according to the manufac­
turer’s protocol (Seegene, Korea). The kit contains sets of pri­
mers that were specifically designed from highly conserved 
re  gions of genetic sequences for HPVs using DPO technology 
[4]. Optimized multiplex PCR was performed in 20 µL reac­
tions containing DNA template, primer mixture, 2X Master 
Mix (Seegene, Korea) and 8­methocypsoralen (MOP), which 
prevents contaminating DNAs for being amplified. PCR ampli­
fication was performed in an Applied Biosystem 9700 thermal 
cycler (Perkin­Elmer, Boston, MA, USA) with the following con­
ditions: After a pre­heating step at 94
oC for 15 minutes, 40 am­
plification cycles were carried out in the thermal cycler under 
the following conditions: denaturation at 94
oC for 30 seconds, 
annealing at 60
oC for 90 seconds, and extension at 72
oC for 90 
seconds. Amplification was completed with a final extension 
step at 72
oC for 10 minutes. The amplified PCR products were 
separated on an auto capillary electrophoresis system, the 
LabChip DX Seeplex Assay system (Caliper, Hopkinton, MA, 
USA).
The PCR products from each sample (20 µL) were transferred 
to a 96 well plate and placed in the LabChip DX instrument. 
The samples were loaded automatically on the Seeplex Chip 
and detected sequentially according to the sample order. 
Analysis was performed with designated software (Seegene 
viewer) that presents each of the samples and identifies the 
fragments that yield a positive readout for the bands of in­
terest in the presented results. A tabulated matching matrix 
provides a simple readout, identifying matching bands to the 
types of HPV. A text file is automatically generated and saved 
for each tape.
6. Cervista HPV HR test and Cervista HPV 16/18 test
The Cervista HPV HR is designed for detection of 14 HPV 
types (i.e., types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 
and 68). The DNA was extracted from residual liquid cytology 
samples that contained at least 2 mL of sample volume, us­
ing the Genfind DNA Extraction Kit (Third Wave Technologies 
Inc./Hologic Inc., Madison, WI, USA), to perform the HR HPV 
and 16/18 genotyping tests. DNA was extracted twice, from 2 
mL aliquots of the original sample, and placed into 2 separate 
cryovials labeled B and C. Cryovial B was used for analysis of 
HR HPV and 16/18 genotyping. Cryovial C was retained for 
long­term storage except when required as backup material. 
The technology for the HR HPV and 16/18 genotyping tests 
has been previously described  [5]. 
7. Statistical analysis
To compare the clinical accuracy of Seeplex HPV4A ACE 
and the Cervista HPV HR test to detect lesions higher than 
low­grade squamous intraepithelial lesions (LSIL), we also 
calculated the sensitivity, specificity, positive predictive value 
(PPV), and negative predictive value (NPV); the sensitivity and 
specificity of the two tests were compared by the receiver 
operating characteristic (ROC) curve in dbSTAT for Windows 
(dBSTAT, Seoul, Korea). Agreement between the HPV assays 
was assessed by Cohen’s κ statistic, with values of 0.00­0.20 
indicating poor agreement, 0.21­0.40 fair agreement, 0.41­
0.60 moderate agreement, 0.61­0.80 substantial agreement, 
and 0.81­1.00 almost perfect agreement. In addition, we used 
the dbSTAT for Windows to compare the predictive values 
between the HR HPV­targeted method and HPV 16 and/or 
18–targeted methods. Statistical analyses were performed 
with SPSS ver. 19.0 (IBM Co., New York, NY, USA) and dBSTAT 
for Windows ver. 4.5 (dBSTAT). All tests were 2­sided, and a P 
value of less than 0.05 was considered significant.
RESULTS
The cytologic findings, as well as all three HPV DNA test 
results, were available for 197 patients. The positive rates of 
each HPV DNA test were 52.3% (103/197) by PCR method, 
45.7% (90/197) by Seeplex HPV4A ACE, and 44.2% (87/197) by 
the Cervista HPV HR test (Table 1). The HR HPV­positive rates 
by PCR, Seeplex HPV4A ACE, and the Cervista HPV HR test 
were 11.0%, 4.0%, and 6.0% for the normal cytology group; 
89.7%, 84.6%, and 82.1% for atypical squamous cells (ASC); 
and 98.2%, 91.4%, and 84.5% for detection of lesions of more 
than LSIL, respectively. 
The concordance for HR HPV detection between the Cervista 
HPV HR test and PCR was 81.7%, showing substantial agree­
ment (κ coefficient=0.636) (Table 2). Additionally, the con­
cordance between Seeplex HPV4A ACE and the Cervista HPV 
HR test was 87.3%, showing substantial agreement (κ coef­
ficient=0.744). For the detection of HPV 16 and/or 18, Seeplex 
HPV4A ACE and the Cervista HPV 16/18 test showed substan­
tial agreement (89.5%, κ coefficient=0.628). 
Table 3 shows the diagnostic accuracy of each HPV DNA test 
related to cytologic results. The overall HR HPV prevalence was 
increased in parallel with the increasing severity of the Pap 
smear result. When an abnormal Pap test was defined as ASCs 
of undetermined significance (ASCUS) or higher, the sensitiv­Kyung-Jin Min, et al.
http://dx.doi.org/10.3802/jgo.2012.23.1.5 8 www.ejgo.org
ity and specificity of Seeplex HPV4A ACE and Cervista HPV HR 
both had high test results. However, Seeplex HPV4A ACE defi­
nitely showed a higher sensitivity and specificity compared to 
Cervista HPV HR (88.7% vs. 83.5% and 96% vs. 94%, respective­
ly) (Table 3). However, no statistical difference was observed 
between the two tests. Likewise, when the abnormal Pap test 
was defined as LSIL or higher, the two HPV DNA tests showed 
no difference for the detection of cytological results. 
We calculated the predictive value for cervical intraepithelial 
neoplasias (CINs) of each HPV test according to cervical histol­
ogy (Fig. 1). In HC2, the predictive value for CINs tended to 
increase with the level of viral load. However, it was difficult 
to identify the exact cutoff value to detect CINs. In the other 
HPV genotyping tests, Seeplex HPV4A ACE, and Cervista HPV 
assays, methods to target HPV 16 and/or 18 had a higher pre­
dictive value than that of HR HPV (66.7% vs. 24.6% by HPV4A 
ACE, 52.6% vs. 25.9% by Cervista HPV assays in CIN II or more, 
relatively, p<0.05).
DISCUSSION
In this study, we found a high efficacy of Seeplex HPV4A ACE 
in detecting HR HPV, HPV 16, and HPV 18 compared with the 
PCR method and Cervista HPV HR and HPV 16/18 tests in HC2­
positive cervical samples. 
Table 1. Results of HPV DNA tests according to cytological diagnosis
Liquid-based cytology No. (%) of positive samples
Results Total PCR HPV4A ACE Cervista HPV HR
Within normal limits 100 11 (11.0) 4 (4.0) 6 (6.0)
Atypical squamous cells 39 35 (89.7) 33 (84.6) 32 (82.1)
Low-grade squamous intraepithelial lesion  44 44 (100.0) 40 (90.9) 36 (81.8)
High-grade squamous intraepithelial lesion 9 8 (88.9) 9 (100.0) 8 (88.9)
Squamous cell carcinoma 5 5 (100.0) 4 (80.0) 5 (100.0)
Total 197 103 (52.3) 90 (45.7) 87 (44.2)
HPV, human papillomavirus; HPV4A ACE, HPV4A auto-capillary electrophoresis; HR, high risk.
Table 2. Concordance among each test for the detection of HR HPV and HPV 16 and/or 18
HPV type HPV DNA test
Agreement
κ*
Positive Negative Overall (%)
HR HPV PCR
HPV4A ACE
HPV4A ACE
Cervista HPV HR
Cervista HPV HR
85
77
76
89
84
96
88.3
81.7
87.3
0.767 
0.636 
0.744 
HPV 16 
and/or 18
PCR
HPV4A ACE
HPV4A ACE
Cervista HPV 16/18
Cervista HPV 16/18
17
16
19
145
132
160
82.2
75.1
89.5
0.402 
0.244 
0.628 
HR HPV, high-risk human papillomavirus; HPV4A ACE, HPV4A auto-capillary electrophoresis. 
*p<0.001.
Table 3. Overview of the diagnostic accuracy of each HPV DNA test according to the results of liquid-based cytology
≥ ASC  ≥ LSIL 
Sensitivity* Specificity* PPV NPV Sensitivity* Specificity* PPV NPV
HPV4A ACE 88.7 96.0 95.6 89.7 91.4 73.4 58.9 95.3
Cervista HPV HR 83.5 94.0 93.1 85.5 84.5 72.7 56.3 91.8
Values are presented as percentage.
HR HPV, high-risk human papillomavirus; ASC, atypical squamous cells including ASCUS and ASC-H; LSIL, low-grade squamous intraepithelial 
lesions; PPV, positive predictive value; NPV, negative predictive value; HPV4A ACE, HPV4A auto-capillary electrophoresis.
*p<0.001 by ROC curve.Usefulness of HPV4A ACE to detect high risk HPV
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The most obvious cause of cervical precursor lesions or can­
cer is persistent infection with one of the carcinogenic HPVs 
[3]. Among those HPVs, the proportion of HPV types 16 and 18 
is the greatest in the development of CIN or cervical cancer [3]. 
It has been shown that women positive for HPV 16 and HPV 
18 have an increased risk of high­grade CIN compared with 
women positive for other HR HPV types [6­9]. For this reason, 
it is important to distinguish HPV 16 and HPV 18 among the 
carcinogenic HPV types.
The Cervista HPV HR is designed to detect all 14 oncogenic 
HPVs and to reduce false­positive results caused by cross­reac­
tivity with low­risk HPV genotypes using signal amplification 
and fluorescence detection. In addition, the Cervista HPV HR 
contains a unique internal control to validate that sufficient 
DNA is present for testing. The Cervista HPV 16/18 test, which 
genotypes for HPV 16/18, is built on same method as Cervista 
HPV HR. Since then, the results of studies regarding the effi­
cacy of Cervista HPV HR and HPV 16/18 have been presented 
by several researchers [5,10­12]. The Seeplex HPV4A ACE test 
can detect 18 HR HPV genotypes. Among these, the common 
primers of HR HPV may detect HPV types 39, 52, and 68 by 
cross­reactivity. Seeplex HPV4A ACE demonstrated substantial 
agreement with PCR (88.3%, κ=0.767). Despite the fact that 
Seeplex HPV4A ACE has not yet been approved by the FDA, 
the efficacy of this test is superior over any other products as 
published previously [13]. This proves the simplicity and reli­
ability of HPV4A ACE for HPV genotyping and screening. If 
two tests have similar abilities to predict abnormal cytology 
or more than CIN II lesions as in our results, it is more useful to 
patients and physicians to use a method that can genotype 
and screen in one test.
In this study, we consider the HC2 assay as the gold standard 
for HR HPV detection, and Seeplex HPV4A ACE and the PCR 
method as a comparative study for HPV 16/18 genotyping. 
After the HC2 assay was approved first by the FDA in 2003, it 
was used as the gold standard in recently published articles 
regarding HPV DNA tests [13­17]. Unfortunately, HC2 can only 
detect the presence of 13 types of HR­HPV. To apply this test 
in an actual clinical situation, it is considered more useful to 
compare its results to those of another currently used meth­
od. For this reason, we decided to use Seeplex HPV4A ACE 
and PCR for genotyping as the real­time PCR technique can 
reinforce the weakness of HC2. Other limitations of this study 
are that this study did not include a negative result of HC2 and 
that this study was conducted retrospectively. In a study con­
ducted by Digene and the National Cancer Institute, an overall 
82.8% agreement (173/209; 95% confidence interval [CI], 77.0 
to 87.6) was observed between HC2 and PCR and a positive 
and negative agreement of 96.7% and 44.6%, respectively 
(95% CI, 92.5 to 98.9 and 31.3 to 58.5). Due to the possibility of 
false positive results of HC2, we should include HC2­negative 
samples for an accurate analysis. However, as mentioned in 
Materials and Methods, HC2­negative samples are difficult 
to collect due to the limitation of this retrospective study. So, 
we took to experiment with the HC2­positive samples, but, 
because of the high overall and positive agreements, we de­
cided to offset the impact that may occur to conduct research 
on HC2­positive samples only.
Seeplex HPV4A ACE has the ability to detect the presence of 
18 HR HPV genotypes in high concordance with PCR simulta­
neously, and it also can identify HPV 16 and/or 18 genotypes 
similar to the Cervista HPV HR test. Seeplex HPV4A ACE has not 
yet received FDA­approval, but it could be said with sufficient 
means as a HPV DNA test. HPV genotyping tests for HPV 16/18 
should be considered to detect CINs more accurately. Seeplex 
HPV4A ACE is strongly recommended for the detection of HR 
HPVs and for genotyping of HPV 16 and/or 18. Continuous 
studies with larger numbers of samples and comparison data 
with other various HPV DNA genotyping methods are neces­
sary to make this novel diagnostic tool more credible and 
practical at the same time. Research is needed that compare 
HPV DNA tests by including all of the HC2 results and serial 
tests on the same target group.
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